Class Action Lawsuit Filed Against Beta Bionics Over Insulin Pump Safety Claims

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has announced the filing of a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) in the United States District Court for the Central District of California. The lawsuit, brought on behalf of investors who purchased or acquired Beta Bionics common stock between July 30, 2025, and February 24, 2026, alleges that the company made materially false and misleading statements about its automated insulin delivery system, the iLet Bionic Pancreas insulin pump.

According to the lawsuit, the Food and Drug Administration (FDA) had raised serious concerns about the iLet device, noting that it was malfunctioning and dosing patients with dangerously high levels of insulin, leading to hypoglycemic events. The lawsuit claims that Beta Bionics downplayed the significance of complaints filed with the FDA, stating that the issues were minor and benign. However, the lawsuit alleges that these complaints numbered in the thousands and included hundreds of life-threatening events that required significant medical intervention.

Furthermore, the lawsuit asserts that Beta Bionics failed to implement any meaningful corrective actions in response to the FDA's concerns. When the true details of the situation became public, the lawsuit claims, investors suffered significant financial losses.

Investors who purchased or acquired Beta Bionics common stock between July 30, 2025, and February 24, 2026, and believe they may have suffered losses are encouraged to contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato. The firm is offering legal advice and assistance to investors who wish to discuss their options.

The lawsuit highlights the importance of transparency and accountability in the medical device industry, particularly when it comes to products that directly impact patient safety. Beta Bionics, a company that develops and markets medical devices for the treatment of diabetes, faces significant scrutiny over its handling of the iLet Bionic Pancreas insulin pump.

Investors have until November 3, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit. The case underscores the potential risks and legal implications associated with the development and marketing of medical devices, especially those that can have life-altering effects on patients.

Bragar Eagel & Squire, P.C., with offices in New York, South Carolina, and California, has a nationwide practice and routinely handles cases in both federal and state courts. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation.